Eugene M. Tulchinsky
Leicester, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Fosl1 is a transcriptional effector of BRAF V600E-driven intestinal tumorigenesis.
Journal: iScience
Published: May 19, 2025
RTK AXL and its Isoforms: Regulation and Implications in Cancer.
Journal: Current medicinal chemistry
Published: January 22, 2025
Proteolysis of TAM receptors in autoimmune diseases and cancer: what does it say to us?
Journal: Cell death & disease
Published: May 13, 2024
Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
Journal: Scientific reports
Published: September 10, 2023
EMT/MET plasticity in cancer and Go-or-Grow decisions in quiescence: the two sides of the same coin?
EMT/MET plasticity in cancer and Go-or-Grow decisions in quiescence: the two sides of the same coin?
Journal: Molecular cancer
Published: April 06, 2023
Zeb1-mediated autophagy enhances resistance of breast cancer cells to genotoxic drugs.
Journal: Biochemical and biophysical research communications
Published: November 19, 2021
AXL Receptor in Cancer Metastasis and Drug Resistance: When Normal Functions Go Askew.
Journal: Cancers
Published: August 11, 2021
The ZEB2-dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancer.
Journal: Molecular oncology
Published: August 20, 2020
Publisher Correction: Zeb2 drives invasive and microbiota-dependent colon carcinoma.
Journal: Nature cancer
Published: July 01, 2020
Zeb2 drives invasive and microbiota-dependent colon carcinoma.
Journal: Nature cancer
Published: March 04, 2020
Protein kinase C inhibitors override ZEB1-induced chemoresistance in HCC.
Journal: Cell death & disease
Published: July 18, 2019
Last Updated: 09/26/2026